Lumenis Announces that the ALLEGRETTO WAVE Excimer Laser Receives FDA Clearance

Hi Allegretto Wavelight Excimer Laser System Researchers. Here is an Article from the Lumenis Company who is the sole distributor of The Allegretto Wavelight Excimer Laser System in the United States of America. It is an old article from 2003 but will be helpful in your research of what Excimer Laser will be the best for you. If I ever had to have lasik it would be with The Allegretto Wavelight Excimer Laser. I bought stock in Lumenis as soon as I read this and it has been going up ever since.

Lasik University

Enjoy the news release and happy researching!

First refractive laser to be granted concurrent approvals for myopia and hyperopia in the United States

<Lasik University

October 21, 2003 - YOKNEAM, Israel

LumenisTM Ltd. (Nasdaq: LUME) announced today that their strategic partner WaveLight Laser Technologie AG of Erlangen, Germany received marketing clearance for the ALLEGRETTO WAVETM Excimer Laser which provides treatment of myopia (nearsightedness) and hyperopia (farsightedness) from the United States Food and Drug Administration (“FDA”). The ALLEGRETTO WAVE is the first refractive laser to receive clearance for both indications with treatment ranges for myopia of up to –12 diopters and with astigmatism of up to –6 diopters. The approval for hyperopia was granted for up to +6 diopters and with astigmatism of up to +5 diopters, not exceeding a mean spherical equivalent of +6 diopters.

“Lumenis is pleased to extend its 30-year track record of pioneering groundbreaking laser systems to the ophthalmic industry by delivering the next generation of refractive technology to the U.S. market,” said Avner Raz, President and Chief Executive Officer of Lumenis. “The excellent performance and results demonstrated in FDA clinical studies we attribute to the laser’s unique ablation profile, which has the capability to achieve unparalleled clinical results in standard LASIK procedures. We believe that the ALLEGRETTO WAVE system will set a new benchmark for standard LASIK treatment in the United States and meets our goal of providing physicians with the highest quality laser products in the marketplace.”

“The FDA approval for the ALLEGRETTO WAVE is the most important milestone that we have reached this year and one of the most important ones in our overall company history. The entire team at WaveLight has devoted tremendous time and effort to make this happen,” stated Max Reindl, Founder and Chief Executive Officer of WaveLight Laser Technologie AG, in an earlier press release.

Lumenis will be the exclusive sales agent in the U.S. responsible for all sales, marketing and field service efforts required to support the ALLEGRETTO WAVE in the U.S. market, in accordance with an exclusive representative agreement with WaveLight Laser Technologie AG. Discussions are continuing regarding licensing arrangements covering the sale of the ALLEGRETTO WAVE in the United States

The existing partnership between Lumenis and WaveLight Laser Technologie AG has successfully captured significant market share of global refractive sales outside the U.S. over the last two years. FDA clearance will allow ophthalmologists to access the German-engineered laser for the first time in the United States, the world’s largest refractive surgery market.

Clinical studies evaluated by the FDA involved treating over 800 eyes with myopia and 290 eyes with hyperopia for refractive vision correction with the ALLEGRETTO WAVE at 11 U.S. clinical sites. The laser will be officially launched at this year’s annual American Academy of Ophthalmology (AAO) meeting, the largest professional conference for ophthalmologists and medical doctors for eye treatments, in Anaheim, California next month.

About WaveLight Laser Technologie AG

WaveLight Laser Technologie AG, noted since January 2003 in the Prime Standard of the German Stock Exchange, develops, produces and distributes laser systems in the field of ophthalmology, aesthetic and urology as well as industrial processing. The innovative and technologically advanced laser systems in conjunction with a broad network of distribution channels and partners are the foundation of the market success of WaveLight. Just five years after entering the market in 1996, WaveLight managed to achieve a positive business result. In the fiscal year 2002/2003 WaveLight reached revenues of 47.8 Million Euros and an EBIT of 4.4. Million Euros.

Further information about WaveLight can be found at www.wavelight-laser.com

About Lumenis

Lumenis develops, manufactures, and markets state-of-the-art proprietary laser and intense pulsed light devices. Its systems are used in a variety of aesthetic, ophthalmic, surgical and dental applications, including skin treatments, hair removal, non-invasive treatment of vascular lesions and pigmented lesions, acne, psoriasis, ENT, gynecology, urinary lithotripsy, benign prostatic hyperplasia, open angle glaucoma, diabetic retinopathy, secondary cataracts, age-related macular degeneration, vision correction, neurosurgery, dentistry and veterinary. For more information about the Company and its products log on to www.lumenis.com

If you would like to conduct more research on The Allegretto Wavelight Laser then please visit Laser Choice


Lasik University